Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II open-label dose-escalation and expansion study of LB1410 combined with LB4330 in advanced or metastatic solid tumors
CTR20241814Phase 2Active
- Sponsor
- L&L Biopharma Co., Ltd.
- Start
- Jul 2024
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of LB1410, LB4330 in Nonhematologic neoplasms, sponsored by L&L Biopharma Co., Ltd.. Started Jul 2024; status: active.
02
Drugs
LB1410LB4330
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20241814.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241814.